INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,726,371 | -15.6% | 33,158 | +2.6% | 0.41% | -6.6% |
| Q2 2023 | $2,045,111 | +10.4% | 32,321 | -5.6% | 0.44% | +7.1% |
| Q1 2023 | $1,853,203 | -4.3% | 34,233 | -5.3% | 0.41% | -5.7% |
| Q4 2022 | $1,935,471 | +11.4% | 36,150 | -3.2% | 0.44% | +8.5% |
| Q3 2022 | $1,737,000 | -24.2% | 37,364 | -7.0% | 0.40% | -17.0% |
| Q2 2022 | $2,293,000 | -3.2% | 40,175 | +3.7% | 0.48% | +36.1% |
| Q1 2022 | $2,370,000 | +16.1% | 38,725 | -0.9% | 0.36% | +33.5% |
| Q4 2021 | $2,042,000 | – | 39,071 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |